Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xultophy

- PMLiVE

Sanofi, GSK’s COVID-19 vaccine generates strong immune responses across all age groups

Sanofi/GSK delayed their COVID-19 vaccine programme in December 2020 after the vaccine candidate induced low immune responses in older adults

- PMLiVE

New court filing alleges Sanofi destroyed emails relating to Zantac recall

Drugmaker began recalling heartburn drug in 2019 after link to probable human carcinogen

- PMLiVE

US backs proposal to waive IP protection for COVID-19 vaccines

"Monumental decision" could see IP protections for COVID-19 vaccines temporarily removed

- PMLiVE

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

Drug reduced lower respiratory tract infections caused by respiratory syncytial virus in infants

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

- PMLiVE

Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Vaccine candidate induced high antibody levels in preclinical studies

- PMLiVE

Sanofi, Regeneron’s Libtayo shows marked reduction in risk of death in cervical cancer patients

Phase 3 trial showed drug reduced the risk of death by 31% compared to chemotherapy

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

Sanofi reports a profit in Q4 as Dupixent sales climb

Shares in the French pharma company climbed around 3% in premarket activity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links